These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22620498)

  • 1. Insights into melanoma: targeting the mTOR pathway for therapeutics.
    Pópulo H; Soares P; Lopes JM
    Expert Opin Ther Targets; 2012 Jul; 16(7):689-705. PubMed ID: 22620498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma.
    Pópulo H; Soares P; Rocha AS; Silva P; Lopes JM
    Melanoma Res; 2010 Apr; 20(2):107-17. PubMed ID: 20173664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
    Wang AX; Qi XY
    IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC.
    Busch C; Geisler J; Lillehaug JR; Lønning PE
    Eur J Cancer; 2010 Jul; 46(11):2127-33. PubMed ID: 20541396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting NRAS in melanoma.
    Kelleher FC; McArthur GA
    Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF, a target in melanoma: implications for solid tumor drug development.
    Flaherty KT; McArthur G
    Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marker utility for combination therapy.
    Simeone E; Grimaldi AM; Ascierto PA
    Methods Mol Biol; 2014; 1102():97-115. PubMed ID: 24258976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New therapies targeting the genetic mutations responsible for different types of melanoma].
    Botella-Estrada R; Sanmartín Jiménez O
    Actas Dermosifiliogr; 2010 Jun; 101(5):394-400. PubMed ID: 20525481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The molecular pathology of cutaneous melanoma.
    Bogenrieder T; Herlyn M
    Cancer Biomark; 2010; 9(1-6):267-86. PubMed ID: 22112480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pathogenesis of cutaneous melanocytic neoplasms.
    Ibrahim N; Haluska FG
    Annu Rev Pathol; 2009; 4():551-79. PubMed ID: 19400696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No evidence for c-erbB-2 overexpression in cutaneous melanoma.
    Fink-Puches R; Pilarski P; Schmidbauer U; Kerl H; Soyer HP
    Anticancer Res; 2001; 21(4A):2793-5. PubMed ID: 11724356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular networks in melanoma invasion and metastasis.
    Aladowicz E; Ferro L; Vitali GC; Venditti E; Fornasari L; Lanfrancone L
    Future Oncol; 2013 May; 9(5):713-26. PubMed ID: 23647299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photodynamic therapy in melanoma--an update.
    Baldea I; Filip AG
    J Physiol Pharmacol; 2012 Apr; 63(2):109-18. PubMed ID: 22653896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localization of radioactive lead in ocular and skin melanoma.
    Packer S; Lambrecht RM; Merrill JC; Atkins HL; Wolf AP
    Invest Ophthalmol; 1975 Jun; 14(6):492-4. PubMed ID: 1132948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The promise of mTOR inhibitors in the treatment of colorectal cancer.
    Kim DD; Eng C
    Expert Opin Investig Drugs; 2012 Dec; 21(12):1775-88. PubMed ID: 22978346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New drug targets in metastatic melanoma.
    Homet B; Ribas A
    J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic alterations and personalized medicine in melanoma: progress and future prospects.
    Griewank KG; Scolyer RA; Thompson JF; Flaherty KT; Schadendorf D; Murali R
    J Natl Cancer Inst; 2014 Feb; 106(2):djt435. PubMed ID: 24511108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular melanoma: a review and the relationship to cutaneous melanoma.
    Hurst EA; Harbour JW; Cornelius LA
    Arch Dermatol; 2003 Aug; 139(8):1067-73. PubMed ID: 12925397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic activation of KIT in distinct subtypes of melanoma.
    Curtin JA; Busam K; Pinkel D; Bastian BC
    J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deciphering the melanoma interactome.
    Reed JA
    J Cutan Pathol; 2008 Nov; 35 Suppl 2():11-5. PubMed ID: 18976413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.